List view / Grid view
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
21 December 2023 | By
A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
Glioblastomas can resist immunotherapy as perivascular fibroblasts support the creation of an immunosuppressive tumour environment.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
In this eBook, discover how to better understand tissue landscapes with different microscopy techniques including multiplex imaging.
Increasing microRNA-22 overexpression in a gene therapy approach treated HCC in mice, offering promise for its prevention and treatment.
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
Carboxylic nanodiamonds could be a therapeutic agent for cancer, as melanoma cells treated with them showed little to no metastasis.
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and…
Eliminating AT1-like cells in experimental models has shown potential to improve KRAS inhibitor treatment for lung adenocarcinoma.
